Treatment of sulphasalazine‐induced agranulocytosis with granulocyte macrophage‐colony stimulating factor
Authors:
- 1 December 1995
- journal article
- case report
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 9 (6) , 711-712
Abstract
SUMMARY: Sulphasalazine‐induced agranulocytosis is a rare but potentially life threatening complication. A variable mortality rate has been reported, from 6% to 20%, and is related to the duration of neutropenia. Previous case reports have shown that the use of granulocyte macrophage‐colony stimulating factor (GM‐CSF) in treating drug‐induced agranulocytosis may shorten the period of neutropenia and hence lead to improved survival. It may also be a less costly treatment option that supportive care alone due to reduction of hospital stay as a consequence of a shortened duration of neutropenia. We report a case in which sulphasalazine had been used in the treatment of ulcerative colitis and the subsequent agranulocytosis was treated successfully with GM‐CSF, something which has hitherto been unreported.Keywords
This publication has 4 references indexed in Scilit:
- Granulocyte-Colony Stimulating Factor Therapy in Drug-Induced AgranulocytosisArchives of internal medicine (1960), 1993
- Sulfasalazine associated agranulocytosis in Sweden 1972–1989European Journal of Clinical Pharmacology, 1992
- Treatment of drug‐induced agranulocytosis with recombinant GM‐CSFJournal of Internal Medicine, 1990
- Drug‐Induced Neutropenia—A Survey for Stockholm 1973–1978Acta Medica Scandinavica, 1982